Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study

被引：0
|
作者：
Fizazi, K. [1 ]
Shore, N. [2 ]
Smith, M. [3 ]
Carles, J. [4 ]
Lebret, T. [5 ]
Lietuvietis, V. [6 ]
Mahammedi, H. [7 ]
Rannikko, A. [8 ]
Vjaters, E. [9 ]
Werbrouck, P. [10 ]
Miskic, M. [11 ]
Kuss, I. [12 ]
Le Berre, M. [13 ]
Borghesi, G. [14 ]
Sarapohja, T. [15 ]
Fayerabend, S. [16 ]
机构：
[1] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Paris, France
[2] Carolina Urol Res Ctr, Atlant Urol Clin, Myrtle Beach, SC USA
[3] Massachusetts Gen Hosp, Genitourinary Canc Ctr, Boston, MA 02114 USA
[4] Vall dHebron Inst Oncol, Dept Oncol, Barcelona, Spain
[5] Hosp FOCH, Dept Urol & Renal Transplantat, Suresnes, France
[6] Riga Eastern Clin Univ Hosp, Urol Clin, Riga, Latvia
[7] Jean Perrin Ctr, Dept Med Oncol, Clermont Ferrand, France
[8] Helsinki Univ Hosp Comprehens Canc Ctr, Dept Urol, Helsinki, Finland
[9] P Stradins Clin Univ Hosp, Urol Ctr, Riga, Latvia
[10] AZ Groeninge, Urol Ctr, Kortrijk, Belgium
[11] Bayer Consumer Care AG, Dept Oncol, Basel, Switzerland
[12] Bayer AG, Dept Clin Dev Oncol, Berlin, Germany
[13] Bayer Healthcare SAS, Dept Clin Stat, Loos, France
[14] Bayer AG, Dept TA Oncol, Berlin, Germany
[15] Orion Corp, Orion Pharma, Espoo, Finland
[16] Studienpraxis Urol, Dept Urooncol, Nuertigen, Germany
来源：
EUROPEAN UROLOGY | 2021年 / 79卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
P1226
引用
收藏
页码：S1740 / S1741
页数：2
相关论文
共 50 条
  • [1] Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study
    Krabbe, L. -M
    Fizazi, K.
    Shore, N.
    Smith, M.
    Carles, J.
    Lebret, T.
    Lietuvietis, V
    Mahammedi, H.
    Rannikko, A.
    Vjaters, E.
    Werbrouck, P.
    Miskic, M.
    Kuss, I
    Le Berre, M. A.
    Borghesi, G.
    Sarapohja, T.
    Feyerabend, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 265 - 265
  • [2] ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Fizazi, Karim
    Shore, Neal D.
    Tammela, Teuvo
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris Y.
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [3] Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial.
    Smith, Matthew Raymond
    Fizazi, Karim
    Tammela, Teuvo L. J.
    Cruz, Felipe Melo
    Nordquist, Luke T.
    Aleman Polanco, Diana Sofia
    Emmenegger, Urban
    Silveira, Glauco Costa
    Concepcion, Raoul S.
    Paula, Adriano
    de Mendonca Beato, Carlos Augusto
    Fleshner, Neil
    Richardet, Martin Eduardo
    Kuss, Iris
    Le Berre, Marie-Aude
    Borghesi, Gustavo
    Sarapohja, Toni
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [4] Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
    Smith, M. R.
    Shore, N. D.
    Tammela, T. L. J.
    Le Berre, M-A.
    Petrenciuc, O.
    Zurth, C.
    Kuss, I.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S1327 - S1328
  • [5] Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
    Fizazi, K.
    Shore, N.
    Smith, M. R.
    Tammela, T. L.
    Le Berre, M-A.
    Petrenciuc, O.
    Zurth, C.
    Kuss, I.
    ANNALS OF ONCOLOGY, 2020, 31 : S522 - S522
  • [6] DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Yu, Evan Y.
    Pieczonka, Christopher Michael
    Armstrong, Andrew J.
    Suzuki, Hiroyoshi
    Bailen, James L.
    Murphy, Declan G.
    Lebret, Thierry
    Luz, Murilo
    Thiery-Vuillemin, Antoine
    Ortiz, Jorge A.
    Khan, Javeed
    Briganti, Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17029 - E17029
  • [7] Safety, tolerability, and duration of continued darolutamide treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study (ROS)
    Fizazi, K.
    Luz, M.
    Ulys, A.
    Ortiz, J.
    Srinivasan, S.
    Kurland, E.
    Shore, N. D.
    EUROPEAN UROLOGY, 2023, 83
  • [8] Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Fizazi, Karim
    Shore, Neal D.
    Tammela, Teuvo
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Le Berre, Marie-Aude
    Petrenciuc, Oana
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Treatment duration and long-term safety and tolerability of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study
    Shore, Neal
    Boegemann, Martin
    Luz, Murilo
    Ulys, Albertas
    Srinivasan, Shankar
    Kurland, Etah
    Fizazi, Karim
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 83 - 83
  • [10] DAROL: DARolutamide ObservationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients.
    Yu, Evan Y.
    Pieczonka, Christopher Michael
    Briganti, Alberto
    Murphy, Declan G.
    Lebret, Thierry
    Luz, Murilo
    Suzuki, Hiroyoshi
    Thiery-Vuillemin, Antoine
    Ortiz, Jorge A.
    Guan, Rongjin
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345